Business
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded contract; topline data readout expected in 2027 SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today
About this update from Dare Bioscience, Inc.
[{"type":"image","alt":"Daré Bioscience, Inc.","displaySize":"","headline":null,"caption":"Daré Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d0Q6BxIcwkh3NEWtzlz17g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853","width":300,"height":114},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/d0Q6BxIcwkh3NEWtzlz17g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853","width":300,"height":114}},"lazy":false},{"type":"text","content":"Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments","length":139,"tagName":"p"},{"type":"text","content":"DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded contract; topline data readout expected in 2027","length":127,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced the initiation of its Phase 2 clinical study of DARE-HPV, an investigational, proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, designed to evaluate DARE-HPV as a potential treatment for persistent high-risk human papillomavirus (HPV) infection.","length":529,"tagName":"p"},{"type":"text","content":"DARE-HPV is being developed as a non-surgical, localized, self-administered therapy designed to clear persistent high-risk HPV infection. HPV infection is the underlying cause of 99% of cervical cancer cases in the United States. There are currently no FDA-approved pharmacologic treatments for HPV infection.","length":309,"tagName":"p"},{"type":"text","content":"The Phase 2 study is a randomized, placebo-controlled, double-blind trial designed to evaluate the safety and antiviral activity of a lower and higher DARE-HPV dose compared with placebo in approximately 100 women with confirmed persistent high-risk HPV infection over an up to 21-day c...